Skip to main content
Premium Trial:

Request an Annual Quote

IntegenX Acquires DNA Consumables Portfolio from GE Healthcare

NEW YORK (GenomeWeb News) – IntegenX today said that it has acquired a portfolio of DNA consumables products from GE Healthcare Bio-Sciences' subsidiary SV Corp.

The acquisition provides Pleasanton, Calif.-based IntegenX with an IP estate covering capillary electrophoresis, separation, sample preparation, and separation matrix technologies, according to IntegenX CEO Stevan Jovanovich.

IntegenX will take over supplying capillaries and matrix to "the more than 100 existing users of GE's MegaBace sequencers," the firm said. Financial and other terms of the deal were not disclosed.

IntegenX intends to integrate the acquired products into its RapidHit 200 Human DNA Identification System, which is scheduled for launch later this year.

The RapidHIT 200 is a sample-to-profile biometric system for real-time human DNA analysis, and according to IntegenX is the first fully automated DNA identification technology that can produce DNA profiles from buccal swabs or other human samples in less than 90 minutes.

Late last year, IntegenX raised $40 million in a Series C round to support further development and commercialization of the system.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.